ArticleBriefings in bioinformatics2026
miRBiT: a rules-based single-sample serum miRNA classifier for pan-cancer detection with multi-cohort validation.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Liquid biopsy offers a minimally invasive approach to early cancer diagnosis. MicroRNAs (miRNAs) are small, non-coding RNAs showing excellent diagnostic potential due to their stability and dysregulation upon different physiological conditions. However, existing miRNA-based cancer classifiers rely on cohort-based comparisons, limiting their clinical utility. Extensive analyses in this study present miRNA binary trend (miRBiT), a miRNA rules-based single-sample classifier, trained on 16,190 samples, tested across nine independent datasets, and further validated on 8 distinct disease cohorts. miRBiT utilizes miRNA expression signatures at an intra-sample level to classify 'cancer' and 'non_cancer' samples, including healthy and other diseases with high sensitivity and specificity, enabling personalized predictions. Additionally, an interactive web application, miRBiT Explorer serum miRNA expression resource, is developed to visualize and validate serum miRNA expression patterns in 46,349 samples. This study highlights the potential of miRNAs in robust cancer classification, enabling personalized, minimally invasive cancer screening and early detection at an unprecedented scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.